HK-listed Metis TechBio, Eli Lilly strike drug-delivery deal worth up to $1.1 billion

Oct 19 (Reuters) – Hong Kong-listed Metis TechBio said on Monday it has entered into a collaboration agreement with Eli Lilly worth up to $1.1 billion to research and develop tissue-specific drug

(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)